JP2017515460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515460A5 JP2017515460A5 JP2016560555A JP2016560555A JP2017515460A5 JP 2017515460 A5 JP2017515460 A5 JP 2017515460A5 JP 2016560555 A JP2016560555 A JP 2016560555A JP 2016560555 A JP2016560555 A JP 2016560555A JP 2017515460 A5 JP2017515460 A5 JP 2017515460A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- identity
- specific car
- hinge
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 47
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 47
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 47
- 210000002865 immune cell Anatomy 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 230000003211 malignant effect Effects 0.000 claims description 5
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 4
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 108020001756 ligand binding domains Proteins 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 230000001086 cytosolic effect Effects 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 210000004896 polypeptide structure Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 3
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201470171 | 2014-04-03 | ||
| DKPA201470171 | 2014-04-03 | ||
| PCT/EP2015/057331 WO2015150526A2 (en) | 2014-04-03 | 2015-04-02 | Cd33 specific chimeric antigen receptors for cancer immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017515460A JP2017515460A (ja) | 2017-06-15 |
| JP2017515460A5 true JP2017515460A5 (Direct) | 2018-04-26 |
| JP6673848B2 JP6673848B2 (ja) | 2020-03-25 |
Family
ID=50486692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016560555A Active JP6673848B2 (ja) | 2014-04-03 | 2015-04-02 | 癌免疫療法のためのｃｄ３３特異的キメラ抗原受容体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9944702B2 (Direct) |
| EP (1) | EP3126390B2 (Direct) |
| JP (1) | JP6673848B2 (Direct) |
| KR (1) | KR102170533B1 (Direct) |
| CN (1) | CN106795221B (Direct) |
| AU (1) | AU2015239069B2 (Direct) |
| CA (1) | CA2944528C (Direct) |
| DK (1) | DK3126390T3 (Direct) |
| ES (1) | ES2765710T3 (Direct) |
| IL (1) | IL247917B (Direct) |
| MX (1) | MX370788B (Direct) |
| RU (1) | RU2701341C2 (Direct) |
| WO (1) | WO2015150526A2 (Direct) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
| US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| CA2944528C (en) * | 2014-04-03 | 2021-08-10 | Cellectis | Cd33 specific chimeric antigen receptors for cancer immunotherapy |
| US10316101B2 (en) * | 2014-04-14 | 2019-06-11 | Cellectis | BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy |
| US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
| US9777061B2 (en) | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11420136B2 (en) | 2016-10-19 | 2022-08-23 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| IL300420B2 (en) | 2015-10-16 | 2024-09-01 | Univ Columbia | Compositions and methods for inhibition of lineage specific antigens |
| CN115960264A (zh) * | 2015-10-30 | 2023-04-14 | 加利福尼亚大学董事会 | 转化生长因子-β应答多肽及其使用方法 |
| CN109715207B (zh) * | 2016-03-29 | 2023-03-31 | 南加利福尼亚大学 | 靶向癌症的嵌合抗原受体 |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| KR102652827B1 (ko) * | 2016-06-08 | 2024-04-01 | 프레시전 인코포레이티드 | Cd33 특이적 키메라 항원 수용체 |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| JP7386082B2 (ja) | 2017-02-28 | 2023-11-24 | ブイオーアール バイオファーマ インコーポレーテッド | 系統特異的タンパク質の阻害のための組成物および方法 |
| JP7137896B2 (ja) * | 2017-03-24 | 2022-09-15 | レンティジェン・テクノロジー・インコーポレイテッド | 抗ｃｄ３３免疫療法によりがんを処置するための組成物および方法 |
| KR20190142775A (ko) | 2017-04-19 | 2019-12-27 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 조작된 항원 수용체를 발현하는 면역 세포 |
| US11529371B2 (en) | 2017-04-24 | 2022-12-20 | Memorial Sloan Kettering Cancer Center | Anti-CD33 antibody agents |
| CN111406068A (zh) | 2017-05-16 | 2020-07-10 | 约翰霍普金斯大学 | MANAbody及使用方法 |
| US11479606B2 (en) | 2017-07-20 | 2022-10-25 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compositions and methods for targeting CD33-expressing cancers |
| EP3687569A1 (en) | 2017-09-29 | 2020-08-05 | Cell Design Labs, Inc. | Methods of making bispecific anti-cd307e and anti-bcma chimeric antigen receptors and uses of the same |
| US12053490B2 (en) | 2017-10-26 | 2024-08-06 | St. Jude Children's Research Hospital, Inc. | Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cells |
| GB201719646D0 (en) * | 2017-11-27 | 2018-01-10 | Bivictrix Therapeutics Ltd | Therapy |
| WO2019113041A1 (en) * | 2017-12-04 | 2019-06-13 | Actinum Pharmaceuticals, Inc. | Methods for treatment of patients with myelodyplastic syndromes |
| EP3725092A4 (en) | 2017-12-14 | 2021-09-22 | FloDesign Sonics, Inc. | DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER |
| CN108047333B (zh) * | 2018-01-15 | 2021-05-25 | 浙江阿思科力生物科技有限公司 | 以cd33为靶点的特异性抗体、car-nk细胞及其制备和应用 |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| SG11202008796VA (en) * | 2018-03-14 | 2020-10-29 | The United States Of America As Represented By The Secretary | Anti-cd33 chimeric antigen receptors and their uses |
| US12280119B2 (en) | 2018-03-23 | 2025-04-22 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| AR115052A1 (es) * | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | Anticuerpos multiespecíficos y utilización de los mismos |
| AR114789A1 (es) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
| CN110551741A (zh) * | 2018-06-01 | 2019-12-10 | 上海恒润达生生物科技有限公司 | 靶向cd33的嵌合抗原受体及其用途 |
| WO2019236577A2 (en) | 2018-06-04 | 2019-12-12 | Intrexon Corporation | Muc16 specific chimeric antigen receptors and uses thereof |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| JP2021527689A (ja) | 2018-06-22 | 2021-10-14 | カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ | キメラ膜貫通タンパク質及びその使用 |
| CN110856724B (zh) * | 2018-08-24 | 2022-05-27 | 杭州康万达医药科技有限公司 | 包含核酸及car修饰的免疫细胞的治疗剂及其应用 |
| WO2020047164A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma, Inc | Genetically engineered hematopoietic stem cells and uses thereof |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| EP3849565A4 (en) * | 2018-09-12 | 2022-12-28 | Fred Hutchinson Cancer Research Center | REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS |
| US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| IL320642A (en) | 2018-11-01 | 2025-07-01 | Gracell Biotechnologies Shanghai Co Ltd | Preparations and methods for engineering T cells |
| CA3118816A1 (en) * | 2018-11-07 | 2020-05-14 | Crispr Therapeutics Ag | Anti-cd33 immune cell cancer therapy |
| WO2020123947A1 (en) | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| AU2020209218A1 (en) * | 2019-01-16 | 2021-07-29 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| US20220195441A1 (en) * | 2019-04-25 | 2022-06-23 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias |
| WO2020223445A1 (en) | 2019-04-30 | 2020-11-05 | Senti Biosciences, Inc. | Chimeric receptors and methods of use thereof |
| CA3142159A1 (en) * | 2019-05-31 | 2020-12-03 | City Of Hope | Cd33 targeted chimeric antigen receptor modified t cells for treatment of cd33 positive malignancies |
| BR112021025735A2 (pt) | 2019-06-21 | 2022-03-08 | Kite Pharma Inc | Receptores de tgf-ss e métodos de uso |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| CN115348973A (zh) * | 2020-03-31 | 2022-11-15 | 弗莱德哈钦森癌症中心 | 靶向cd33的嵌合抗原受体 |
| CN115335396A (zh) * | 2020-03-31 | 2022-11-11 | 弗莱德哈钦森癌症中心 | 靶向cd33的嵌合抗原受体 |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| CR20230263A (es) | 2020-12-17 | 2023-08-21 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de estos |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| AU2022291365A1 (en) | 2021-06-08 | 2024-01-18 | Kite Pharma, Inc. | Gpc3 binding molecules |
| WO2022266075A1 (en) | 2021-06-14 | 2022-12-22 | Caribou Biosciences, Inc. | Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain |
| CN113527435B (zh) * | 2021-07-14 | 2022-06-07 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 对前列腺癌细胞特异性识别的新型多肽及其衍生物与应用 |
| GB202204386D0 (en) * | 2022-03-28 | 2022-05-11 | Cambridge Entpr Ltd | Engineered immune cell platform |
| WO2025008108A1 (en) | 2023-07-06 | 2025-01-09 | Miltenyi Biotec B.V. & Co. KG | Immune cell expressing chimeric antigen receptor and transgenic t cell receptor |
| WO2026008700A1 (en) | 2024-07-03 | 2026-01-08 | Immunofusion Bv | Il7r alpha signalling domain, chimeric antigen receptor and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030229208A1 (en) * | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE207366T1 (de) * | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| MXPA05004712A (es) * | 2002-11-07 | 2005-11-23 | Immunogen Inc | Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos. |
| DE102009045006A1 (de) * | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| HRP20190556T1 (hr) * | 2009-11-03 | 2019-06-14 | City Of Hope | SKRAĆENI OBLIK RECEPTORA EPIDERMALNOG FAKTORA RASTA ZA (EGFRt) ODABIR TRANSDUCIRANIH T-STANICA |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| PL2855667T3 (pl) | 2012-05-25 | 2024-03-25 | Cellectis | Sposoby uzyskiwania metodami inżynierii allogenicznych i opornych na immunosupresję limfocytów t do immunoterapii |
| CA2944528C (en) * | 2014-04-03 | 2021-08-10 | Cellectis | Cd33 specific chimeric antigen receptors for cancer immunotherapy |
| US10316101B2 (en) * | 2014-04-14 | 2019-06-11 | Cellectis | BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy |
-
2015
- 2015-04-02 CA CA2944528A patent/CA2944528C/en active Active
- 2015-04-02 ES ES15713513T patent/ES2765710T3/es active Active
- 2015-04-02 JP JP2016560555A patent/JP6673848B2/ja active Active
- 2015-04-02 RU RU2016143155A patent/RU2701341C2/ru active
- 2015-04-02 CN CN201580027233.3A patent/CN106795221B/zh active Active
- 2015-04-02 KR KR1020167030892A patent/KR102170533B1/ko active Active
- 2015-04-02 DK DK15713513.8T patent/DK3126390T3/da active
- 2015-04-02 US US15/301,686 patent/US9944702B2/en active Active
- 2015-04-02 MX MX2016012855A patent/MX370788B/es active IP Right Grant
- 2015-04-02 EP EP15713513.8A patent/EP3126390B2/en active Active
- 2015-04-02 WO PCT/EP2015/057331 patent/WO2015150526A2/en not_active Ceased
- 2015-04-02 AU AU2015239069A patent/AU2015239069B2/en active Active
-
2016
- 2016-09-19 IL IL247917A patent/IL247917B/en active IP Right Grant
-
2018
- 2018-03-20 US US15/926,755 patent/US20190002561A1/en not_active Abandoned
-
2023
- 2023-10-26 US US18/495,109 patent/US20240182565A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515460A5 (Direct) | ||
| JP2017509342A5 (Direct) | ||
| RU2016143155A (ru) | Cd33-специфические химерные антигенные рецепторы для иммунотерапии рака | |
| JP2017513478A5 (Direct) | ||
| JP2018029594A5 (Direct) | ||
| JP2018504143A5 (Direct) | ||
| Zhao et al. | The MHC class I‐LILRB1 signalling axis as a promising target in cancer therapy | |
| Tai et al. | B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma | |
| Jafari et al. | Fc-fusion proteins in therapy: an updated view | |
| JP2017527275A5 (Direct) | ||
| JP2020503891A5 (Direct) | ||
| Dharmadhikari et al. | CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses | |
| JP2016538830A5 (Direct) | ||
| JP2022109953A5 (Direct) | ||
| RU2017102769A (ru) | EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА | |
| JP2019530431A5 (Direct) | ||
| JP2018513216A5 (Direct) | ||
| JP2018504459A5 (Direct) | ||
| JP2018504145A5 (Direct) | ||
| FI3703750T3 (fi) | B-solujen maturaatioantigeenille spesifisiä kimeerisiä antigeenireseptoreita ja koodaavia polynukleotideja | |
| JP2015527070A5 (Direct) | ||
| JP2018508219A5 (Direct) | ||
| RU2015153250A (ru) | Cd19-специфический химерный антигенный рецептор и его применения | |
| HRP20230297T1 (hr) | UPRAVLJANJE TOKSIČNOŠĆU ZA ANTI-TUMORSKO DJELOVANJE CAR-a | |
| JP2016514462A5 (Direct) |